Pemazyre® (pemigatinib) – New indication
August 26, 2022 - Incyte announced the FDA approval of Pemazyre (pemigatinib), for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
Download PDF
